Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
12. Dezember 2024 08:00 ET
|
Precede Biosciences, Inc.
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field todayThere are approximately...
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
15. November 2024 21:15 ET
|
Precede Biosciences, Inc.
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMABeyond Lutetium-PSMA, these results are...
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
19. September 2024 10:50 ET
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
15. September 2024 06:05 ET
|
Precede Biosciences, Inc.
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET...
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
02. Juni 2024 10:00 ET
|
Precede Biosciences, Inc.
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancersER status was accurately assessed and the level of ER pathway activation quantified in 87...
Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test
10. April 2024 12:19 ET
|
Precede Biosciences, Inc.
Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancersTargets revealed from a...
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024
05. März 2024 16:35 ET
|
Precede Biosciences, Inc.
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced three...
Data Presented at SABCS Demonstrate the Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform to Define HER2 and ER Status in Patients With Advanced Breast Cancer
06. Dezember 2023 08:00 ET
|
Precede Biosciences, Inc.
BOSTON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced that...
Data Demonstrating Precede Biosciences' Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium
28. November 2023 17:02 ET
|
Precede Biosciences, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data...
Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine
21. Oktober 2023 04:25 ET
|
Precede Biosciences, Inc.
Pivotal findings stem from Precede’s first-in-class platform in collaboration with Dana-Farber Cancer Institute Results underscore the immense potential of the blood-based platform to impact...